Price T Rowe Associates Inc Avidity Biosciences, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 11,338,098 shares of RNA stock, worth $343 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
11,338,098
Previous 11,042,823
2.67%
Holding current value
$343 Million
Previous $321 Million
4.23%
% of portfolio
0.04%
Previous 0.04%
Shares
18 transactions
Others Institutions Holding RNA
# of Institutions
244Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$345 Million0.19% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$293 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$279 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$264 Million4.23% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$261 Million0.01% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.58B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...